Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 6/20 | 0.52 |
| ▸ | PDK2 | Q15119 | 10/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24304935 | 0.85 | FEN1 (0.54) | FEN1MAPTNTRK1ALK | |
| SCHEMBL24304544 | 0.82 | PKM (0.43) | FEN1POLBMAPTALOX5AP | |
| SCHEMBL2625723 | 0.81 | CCNT1 (0.51) | FEN1MAPTALKALOX5AP | |
| SCHEMBL24304940 | 0.78 | FEN1 (0.60) | FEN1PDK2TGFBR1PDK1PDK3 | |
| SCHEMBL1703117 | 0.74 | ALDH1A1 (0.55) | POLBMAPT | |
| SCHEMBL24157831 | 0.71 | FEN1 (0.45) | FEN1MAPTALK | |
| SCHEMBL24304323 | 0.71 | DYRK1A (0.47) | NTRK1 | |
| SCHEMBL14809788 | 0.71 | CYP19A1 (0.52) | POLBMAPT | |
| SCHEMBL9807395 | 0.71 | ELANE (0.50) | POLBMAPTATM | |
| SCHEMBL18193018 | 0.71 | ALDH1A1 (0.45) | MAPTATMALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119370-A1 | BRD4-JAK2 INHIBITORS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119370-A1 | BRD4-JAK2 INHIBITORS | BRD4, BICRA, JAK2 | FEN1 4488/4885PDK2 1204/4885TGFBR1 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.